Letter: severe COVID-19 infection and biologic therapies-a cohort study of 7808 patients in France. Authors' reply
- PMID: 33016549
- DOI: 10.1111/apt.16055
Letter: severe COVID-19 infection and biologic therapies-a cohort study of 7808 patients in France. Authors' reply
Comment on
-
Letter: severe COVID-19 infection and biologic therapies-a cohort study of 7 808 patients in France.Aliment Pharmacol Ther. 2020 Oct;52(7):1245-1248. doi: 10.1111/apt.16040. Aliment Pharmacol Ther. 2020. PMID: 33016546 No abstract available.
References
REFERENCES
-
- Bataille P, Amiot A, Claudepierre P, et al. Letter: severe COVID-19 infection and biologic therapies - a cohort study of 7 808 patients in France. Aliment Pharmacol Ther. 2020;52:1245-1248.
-
- Taxonera C, Sagastagoitia I, Alba C, et al. 2019 Novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2020;52:276-283.
-
- Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108:1268-1276.
-
- Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033-1034. [Epub ahead of print].
-
- Brenner EJ, Ungaro RC, Colombel JF, Kappelman MD.IBD Database public data update. https://covidibd.org/current-data/2020 (accessed Jul 26 2020)
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources